港股異動丨核心產品授權出海反遭市場爆錘,榮昌生物大跌超25%
昨日一度創出階段新高的榮昌生物今日AH股齊暴跌,A股一度封跌停板,20CM跌停,報價59.48元;H股一度跌超25%至50.05港元。消息面上,榮昌生物今早公告,公司將具有自主知識產權的泰它西普有償許可給美國Vor Bio公司,美國Vor Bio公司將獲得在除大中華區以外的全球範圍內開發和商業化的獨家權利。作爲對外許可交易對價一部分,榮昌生物及其全資附屬主體榮普合夥將從美國Vor Bio公司取得價值1.25億美元現金及認股權證(4500萬美元首付款及8000萬美元認股權證)。基於臨牀開發進度及上市的銷售情況,Vor Bio公司還將支付最高可達41.05億美元的臨牀註冊及商業化里程碑付款,以及高個位數至雙位數銷售提成款。有業內人士指出,從今天榮昌生物股價的反應來看,市場並不滿意此次核心產品授權出海的結果,或者說與預期有一定的差距。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.